Teal Health, a San Francisco, CA-based provider of a women’s health platform, raised $8.8M in Seed funding.
The backers were Serena Ventures, Metrodora, and Emerson Collective.
The company intends to use the funds to expedite product development, clinical testing, and FDA approval.
Led by CEO Kara Egan, Teal Health is on a mission to provide women with the tools and resources they need to make empowered and informed decisions regarding their health—starting with cervical cancer screenings. The company’s at-home cervical cancer screening includes a novel self-collection device that will make it simple for a woman to collect a cervical cancer screening sample from the comfort, convenience, and privacy of her home. It’s designed to increase a woman’s confidence and adherence to screen for primary HPV and Pap cytology triage. The Teal Health platform will enable conversation and engagement with medical professionals to support users, from collecting a sample to understanding results, including any follow-up actions.
Teal Health’s clinical study is underway at leading institutions and women’s health organizations such as The University of Wisconsin-Madison and Planned Parenthood Gulf Coast. Early data found that 89% of women said that if Teal’s at-home collection were available, they would get screened on time. The self-collection option is preferred by 91% of study participants when compared to a clinical collection with a speculum.
FinSMEs
31/01/2023